Vonjo (Pacritinib) for Myeloproliferative Neoplasms

Overview
Vonjo is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with certain types of myelofibrosis. Vonjo is also known by its generic name, pacritinib.

Vonjo is part of a class of medications called kinase inhibitors. Scientists believe it works by blocking an abnormal protein that signals cancer cells to propagate (multiply), thereby stopping or slowing the spread of cancer cells.

How do I take it?
Vonjo is available as an oral 100-milligram capsule and is usually taken twice daily, with or without food. It should be taken at the same time every day.

Side effects
The most common side effects of Vonjo are diarrhea, thrombocytopenia (low platelet count), nausea, anemia (low red blood cell count), and peripheral edema (swelling in lower legs and hands).

Rare but serious side effects include severe bleeding, severe diarrhea, worsening thrombocytopenia, QTc prolongation (changes in electrical activity in the heart), major cardiovascular events (e.g., heart attack or stroke), thrombosis (blood clots), development of new cancers, and infection.

For more details about this treatment, visit:

Pacritinib — MedlinePlus
https://medlineplus.gov/druginfo/meds/a622043.html

Vonjo — Drugs.com
https://www.drugs.com/vonjo.html